Fate Therapeutics gives Q3 2026 update on lupus CAR T program and FT839 trial sitesNov 10Regulatory decisionAutolus Therapeutics plcFate TherapeuticsUpdated
FDA updates fludarabine phosphate labeling under Project RenewalNov 9Regulatory decisionFludarabinefludarabine phosphate
Beth Israel registers Phase II lifileucel TIL trial for kidney cancer with IovanceNov 9Trial updatealdesleukinIovance Biotherapeutics, Inc.
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
Nkarta to webcast initial NKX019 data in autoimmune disease at ACR 2026Nov 6PublicationNkarta, Inc.NKX019
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
AstraZeneca completes balcinrenone/dapagliflozin PK study; posts two new observational trialsOct 23Weekly roundup, 12 itemsabemaciclibAstraZeneca
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Kite's ZUMA-2 Cohort 3 trial in BTKi-naive mantle cell lymphoma completes, results postedAug 18Trial updatebrexucabtagene autoleucelFludarabine
Nkarta reports Q2 2026 results, continued enrollment in autoimmune NK-cell trialsAug 10Quarterly updateNkarta, Inc.
Novartis: Mayzent label update approved; four real-world studies registered or recruitingJul 2Weekly roundup, 7 itemsalpelisibFludarabine